Last reviewed · How we verify

Ethyol — Competitive Intelligence Brief

Ethyol (AMIFOSTINE) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: amifostine. Area: Oncology.

marketed amifostine D(3) dopamine receptor Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Ethyol (AMIFOSTINE) — Cosette. Ethyol works by protecting the kidneys and salivary glands from damage caused by chemotherapy and radiation.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Ethyol TARGET AMIFOSTINE Cosette marketed amifostine D(3) dopamine receptor 1995-01-01
Pramipexole (Mirapex) Pramipexole (Mirapex) Massachusetts General Hospital marketed Dopamine agonist D2 dopamine receptor, D3 dopamine receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (amifostine class)

  1. Cosette · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ethyol — Competitive Intelligence Brief. https://druglandscape.com/ci/amifostine. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: